XTX Topco Ltd Buys Shares of 8,862 Tempus AI, Inc. (NASDAQ:TEM)

XTX Topco Ltd purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,862 shares of the company’s stock, valued at approximately $502,000.

Other hedge funds have also recently modified their holdings of the company. NEA Management Company LLC increased its stake in Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after buying an additional 813,169 shares during the period. Novo Holdings A S purchased a new stake in shares of Tempus AI in the second quarter valued at about $142,605,000. Revolution Growth Management Company Inc. acquired a new position in shares of Tempus AI during the second quarter worth about $128,133,000. ARK Investment Management LLC raised its holdings in Tempus AI by 355.0% during the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after purchasing an additional 1,855,459 shares in the last quarter. Finally, Alphabet Inc. acquired a new stake in Tempus AI in the second quarter valued at about $54,289,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital raised their target price on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday. They set an “outperform” rating and a $60.00 price target on the stock. Finally, Guggenheim initiated coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.00.

Insider Buying and Selling at Tempus AI

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the transaction, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at $10,431,543.15. The trade was a 17.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 650,949 shares of company stock valued at $27,821,944 over the last quarter.

Tempus AI Trading Down 2.4 %

Tempus AI stock opened at $41.00 on Friday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49. The stock has a 50-day simple moving average of $52.64. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.